Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MXnDfZRwfG:6aXOgRZN{[Xl? NWLDRlBqPTBizszN M2GzN|Q5KGh? NIPJb2ZFVVOR NFTpVVFMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm M{\3SlExPDl7NkSz
OVCA 429 MXHGeY5kfGmxbjDBd5NigQ>? M{HKWFMxOCCwTR?= M2LHfVQ5KGh? NWfsXVB4TE2VTx?= NInN[GZFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> NWDK[2dZOTB7OUm3OlY>
RPMI8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33iVVExOCCwTR?= MoK0OFghcA>? MoW3SG1UVw>? M{CwR2lEPTB;M{Cgcm0> M336OVEyOzB4NEi5
Dox40 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxNFAhdk1? MUS0PEBp NF:5VmFFVVOR M4Tm[mlEPTB;NECgcm0> MYmxNVMxPjR6OR?=
MR20 M3\uUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexO3gyODBibl2= MXi0PEBp M1jMb2ROW09? NX\5d2YxUUN3ME2yNEBvVQ>? MXmxNVMxPjR6OR?=
LR5 NYj3UIlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rtclExOCCwTR?= MVK0PEBp M4LKe2ROW09? NYrkeY41UUN3ME2yNEBvVQ>? NGSyd3QyOTNyNkS4PS=>
U266 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNFAhdk1? NVv0S2dFPDhiaB?= MUnEUXNQ NEfGPWVKSzVyPUOgcm0> MUmxNVMxPjR6OR?=
IM-9 NWTOVmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3RXh1OTByIH7N NGPIZZk1QCCq NGPwPVdFVVOR MmW5TWM2OD14IH7N NVjXN|hIOTF|ME[0PFk>
Hs Sultan Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzNTGFzOTByIH7N NW\Hcno5PDhiaB?= M4LMfGROW09? M1v1[mlEPTB;MkCgcm0> M{W5XVEyOzB4NEi5
PAM-LY2 MXfGeY5kfGmxbjDBd5NigQ>? M4X5[FExOCCwTR?= M{Tqd|EzKGh? NELab4ZFVVOR M2fEOGlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u M4XEe|EyOzVyOUGz
PAM 212 M3q2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNFAhdk1? M4TGU|czKGh? MoPCSG1UVw>? MYPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NVXue3IxOTF|NUC5NVM>
PAM-LY2 NXm0fXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknZNVAxKG6P NGftXIM4OiCq MXfEUXNQ M4r0UmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NGLmUGsyOTN3MEmxNy=>
B4B8 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xi[|ExOCCwTR?= Mn\yO|IhcA>? MVXEUXNQ MUPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NGnoeFIyOTN3MEmxNy=>
B7E3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfuNVAxKG6P NYPhfmtGPzJiaB?= MmL2SG1UVw>? NH[zTphKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MUexNVM2ODlzMx?=
UM-SCC-9 M3W3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TvVVExOCCwTR?= M1zCUVczKGh? NFv4bpFFVVOR M4DWdGlvcGmkaYTzJINmdGxidnnhZoltcXS7 MXmxNVM2ODlzMx?=
UM-SCC-11B MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv2VHlYOTByIH7N NVvx[YU5PzJiaB?= NGPwcHpFVVOR NEHiVHRKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MVyxNVM2ODlzMx?=
H460 NETDVVRHfW6ldHnvckBCe3OjeR?= MUSxNEDPxE1? MoXmNlQhcA>? NH3ZRnRFVVOR MYfJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 MVGxNlQ6OjFzNx?=
U266 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn4O|A2ODBibnevcYw> M3TadlQ5KGh? Mn;lSG1UVw>? MojLTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnHYNVI3OzF4MUm=
ARH77 M3vVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnNlUxOCCwZz;tcC=> MkD5OFghcA>? MWHEUXNQ MlrzTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M17JPVEzPjNzNkG5
WAD-1 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW1NFAhdmdxbXy= NWTqSWFjPDhiaB?= Moi4SG1UVw>? M1XKUmlvcGmkaYTzJINmdGxiZ4Lve5Rp MYmxNlY{OTZzOR?=
U266/LR7 NVfBUY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjoW2I2ODBibnevcYw> NISwUHg1QCCq M2W5[mROW09? NH\mbpBKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mn;oNVI3OzF4MUm=
U266/dox4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[1NFAhdmdxbXy= MX60PEBp MkDMSG1UVw>? M17hUWlvcGmkaYTzJINmdGxiZ4Lve5Rp NUPjPGxiOTJ4M{G2NVk>
RPMI8226/LR5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO1NFAhdmdxbXy= NGHOPIU1QCCq M4m3VmROW09? NFzNc4NKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NV7W[o5rOTJ4M{G2NVk>
H460 NGLHXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PzXFExKM7:TR?= NHfacWs4OiCq NUX6Snp{TE2VTx?= M4DRNmlEPTB;MUCwJI5O MlXBNVI3OzF4MkC=
H358 M2PSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7sNVAh|ryP NEnre4I4OiCq MUDEUXNQ MmTDTWM2OD15MDDuUS=> NXXHdm86OTJ4M{G2NlA>
H322 NVfINGZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn3NVAh|ryP Ml3nO|IhcA>? M1Oye2ROW09? NF70botKSzVyPU[yNEBvVQ>? NVjBTmF3OTJ4M{G2NlA>
H460 MVXGeY5kfGmxbjDBd5NigQ>? NV;EeIp3OTByIH7N MYGyOEBp M3TH[WROW09? M1jxWGlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? MYqxNlY{OTZ{MB?=
LNCap-Pro5 NX7PZodlTnWwY4Tpc44hSXO|YYm= M2fSN|Eh|ryP NGTnfGg1KGh? MnrGSG1UVw>? M4WyeXN1[WKrbHn6[ZMheDV| M2DKcVE1PjF{NUOy
T29 M33lS2Fxd3C2b4Ppd{BCe3OjeR?= MXi1NEBvVQ>? NVq1cGg3PDhiaDC= MXjEUXNQ NUewOIZFUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVrjZ5FZOTZ5N{ixO|k>
T29Kt1 MUDBdI9xfG:|aYOgRZN{[Xl? NXzyeHp2PTBibl2= M4KzVVQ5KGhi NFTMZphFVVOR M{XobGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MoX2NVY4PzhzN{m=
HCT116 MXrBdI9xfG:|aYOgRZN{[Xl? M2rh[lUxKG6P MYe0PEBpKA>? M1TVOWROW09? NFK4PJpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4XNeFE3Pzd6MUe5
HKe-3 NXnt[GQ5SXCxcITvd4l{KEG|c3H5 MXK1NEBvVQ>? MXS0PEBpKA>? NHPMepZFVVOR MXnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmTSNVY4PzhzN{m=
NB-1691 NELjUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETVNnAyKM7:TR?= Mo\aO|IhcA>? MY\Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? MYGxO|Y5QTZ6NB?=
CHLA-255 NE\4dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsZ3NDOSEQvF2= NYnFZ3dVPzJiaB?= NYOyb3k2UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl MWWxO|Y5QTZ6NB?=
SK-N-AS MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2zS25VOSEQvF2= NU[wTY5LPzJiaB?= MWjJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NIDhVmgyPzZ6OU[4OC=>
NB-1691 NY\k[HRHTnWwY4Tpc44hSXO|YYm= NVTFfW5LOTBibl2= M3v4UVI1KGh? NH7WdXdUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm NI\HU5oyPzZ6OU[4OC=>
CHLA-255 M13vO2Z2dmO2aX;uJGF{e2G7 NG\zV3YyOCCwTR?= NYPjSIlZOjRiaB?= NYO5bGhoVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= NHjsRWcyPzZ6OU[4OC=>
RPMI 8226 NEPSUo5HfW6ldHnvckBCe3OjeR?= NUHlO|JmOjBibl2= NVfpfHNwQCCq NVzRbIFUW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M175TVE6PDN4MEWw
MM.1S NIDHRnVHfW6ldHnvckBCe3OjeR?= M{HrWFIxKG6P NGj5WIU5KGh? NEjIbIpUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? Mli4NVk1OzZyNUC=
U266 MULGeY5kfGmxbjDBd5NigQ>? NIH4NFgzOCCwTR?= M4nZRlghcA>? NFfjVHlUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MVuxPVQ{PjB3MB?=
OPM1 M3XScGZ2dmO2aX;uJGF{e2G7 MmT4NlAhdk1? MnT3PEBp NF3jdZZUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MmfBNVk1OzZyNUC=
INA6 NFrVSFVHfW6ldHnvckBCe3OjeR?= NGrRW48zOCCwTR?= MU[4JIg> Ml[4V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M{T3dlE6PDN4MEWw
OPM2 NHXRXJlHfW6ldHnvckBCe3OjeR?= M{HC[VIxKG6P MV:4JIg> M3fsfnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NFjBcZoyQTR|NkC1NC=>
RPMI 8226 M1jyTWZ2dmO2aX;uJGF{e2G7 MV6yNEBvVQ>? NYLi[olWQCCq NFPrfY1KdmS3Y3XzJGRPSSC|eX70bIV{cXN? NHTHc24yQTR|NkC1NC=>
BaF/3 NE\MVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkNVAxKG6P MlXsOFghcA>? M1npXWlEPTB;Nj6yJI5O MoC5NlA{ODV4OUK=
BaF/3-p210 NUDLUY9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNFAhdk1? NGPOcFU1QCCq MljyTWM2OD12Lkegcm0> Mnf1NlA{ODV4OUK=
TCC-S MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjJbXVoOTByIH7N M3\ETFQ5KGh? M2\NVGlEPTB;Mj64JI5O MXuyNFMxPTZ7Mh?=
BaF/3 MVHGeY5kfGmxbjDBd5NigQ>? NWTPWlNNPiCwTR?= M4\Md|Q5KGh? Mn;MTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 MWqyNFMxPTZ7Mh?=
BaF/3-p210 MXnGeY5kfGmxbjDBd5NigQ>? MX22JI5O M1nKWlQ5KGh? MWLJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 M1LvNlIxOzB3Nkmy
BaF/3-p210 MWPGeY5kfGmxbjDBd5NigQ>? MkSxOkBvVQ>? MoG5NlQhcA>? NX64SmhqWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= NVnzfXZwOjB|MEW2PVI>
Raji Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxJO69VQ>? NGL2eoMzPCCq MVrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{f1OlIyOTdyOUi4
LCL-1 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxJO69VQ>? MYGyOEBp NUfm[2g6WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M2\oeVIyOTdyOUi4
LCL-2 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYexJO69VQ>? NGX5bogzPCCq MVPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{XNVVIyOTdyOUi4
BJAB NIi4W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn73NUDPxE1? MnjYNlQhcA>? NWHRNIp{WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NYjIboprOjFzN{C5PFg>
SNT-13 M2XOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHMfGkyKM7:TR?= MnvWNlQhcA>? NXTPdlQ5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M1\sTFIyOTdyOUi4
SNT-16 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxJO69VQ>? M1H5NVI1KGh? NVz6c3pXWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NF70ZowzOTF5MEm4PC=>
Jurkat NWjhb5Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvrNUDPxE1? MV2yOEBp MY\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NF2xTYszOTF5MEm4PC=>
KAI-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Sb|Eh|ryP NFexdGQzPCCq MYLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NVnHOW5NOjFzN{C5PFg>
SNK-6 NYjsS49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX5b25VOSEQvF2= M1rYXVI1KGh? NX;4Rm0xWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXKyNVE4ODl6OB?=
KHYG-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xJO69VQ>? NGDtc5QzPCCq MoDIVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi Mm\mNlEyPzB7OEi=
SNT-16 M{TDdGFxd3C2b4Ppd{BCe3OjeR?= NUG2SIZzOSEQvF2= MX:2JIg> M1nhSWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2fhWFIyOTdyOUi4
Jurkat M2K3[mFxd3C2b4Ppd{BCe3OjeR?= NWGxd2VTOSEQvF2= MUi2JIg> MXTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MX[yNVE4ODl6OB?=
KAI-3 M3zQemFxd3C2b4Ppd{BCe3OjeR?= M{jydFEh|ryP NX[3T3pbPiCq NH7EfHNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4LTOlIyOTdyOUi4
KHYG-1 M2j3ZWFxd3C2b4Ppd{BCe3OjeR?= MkfPNUDPxE1? MlLuOkBp MkL4TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVTUU|RHOjFzN{C5PFg>
SNT-13 MlzBRY51cX[rcnHsJGF{e2G7 MWCxJO69VQ>? M2TLeFI1KGh? NGrTNWpKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? M1LvTlIyOTdyOUi4
SNT-16 MnfpRY51cX[rcnHsJGF{e2G7 M3vNUFEh|ryP NWDJfJppOjRiaB?= NHnOcplKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MYKyNVE4ODl6OB?=
KAI-3 NGHTXpRCdnSrdnnyZYwhSXO|YYm= M3HEWlEh|ryP MnTsNlQhcA>? NWj3ZXJ{UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MV6yNVE4ODl6OB?=
SNK-6 MkPaRY51cX[rcnHsJGF{e2G7 MYWxJO69VQ>? NWq3eJp[OjRiaB?= M17oSmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MWKyNVE4ODl6OB?=
RAW 264.7 NWe3eWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV60UlI1OTByIH7N M1zNVFQ5KGh? NHXtRpFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NECwcI4zOjR{N{G1OC=>
A375 NF71O5JCeG:ydH;zbZMhSXO|YYm= MortNVAhdk1? M2Dq[VI1KGh? MmHRTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NG\nW2EzOzB5OUC4Ny=>
BLM M{i3[GFxd3C2b4Ppd{BCe3OjeR?= MoLDNVAhdk1? MnzVNlQhcA>? MW\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHfu[ZQzOzB5OUC4Ny=>
A375 M1:ydGF2fG:yaHHnfUBCe3OjeR?= NWHLZVY3OTBibl2= NXP0cXJPOTJiaB?= MYjJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MWKyN|A4QTB6Mx?=
BLM NY\CTVh{SXW2b4DoZYd6KEG|c3H5 MX2xNEBvVQ>? MlrsNVIhcA>? NI\5TpBKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NGry[2EzOzB5OUC4Ny=>
H1299 M1LzSGFxd3C2b4Ppd{BCe3OjeR?= NETjb2M5OCCwTR?= MWeyOEBp Mn3SSG1UVw>? NFK2XnpU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= MXKyOVMzOzZ7Mx?=
Hut-78 MnS4SpVv[3Srb36gRZN{[Xl? MXyxNFAhdk1? MXuyOEBp NXPyU2c6TE2VTx?= M2rUWmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NITBeYUzPTZ6MUOzOS=>
H9 NWTTNlY5TnWwY4Tpc44hSXO|YYm= NX;5eZlkOTByIH7N MlPlNlQhcA>? MUjEUXNQ NVHHVmV4TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u MmLkNlU3QDF|M{W=
HH M2K1TGZ2dmO2aX;uJGF{e2G7 Mlf3NVAxKG6P NG\ycokzPCCq M3XEWmROW09? Ml3y[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w MlO1NlU3QDF|M{W=
Hut-78 M1LxSm1q\3KjdHnvckBCe3OjeR?= M2rtbFExOCCwTR?= NHXaeoQzPCCq NVe4dopbTE2VTx?= NITLWHRT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl NX;wS3V{OjV4OEGzN|U>
HH NV3xZoVlVWmpcnH0bY9vKEG|c3H5 M2jBWVExOCCwTR?= M{flNVI1KGh? NHzNWJVFVVOR NGLkO3dT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl Mne1NlU3QDF|M{W=
U937 MYLGeY5kfGmxbjDBd5NigQ>? NILEblcyODBibl2= MVS2JIg> Ml61TY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? MoXCNlU4QTF2N{e=
human PBMC M{nubmZ2dmO2aX;uJGF{e2G7 Mm\XNVAxKG6P MX6yOEBp MU\JcoR2[2W|IFnMMVghemWuZXHz[S=> NGH3PG4zPTd7MUS3Oy=>
ES6 M{DIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M131S2lEPTB;MD6wNFIyKG6P Mki1V2FPT0WU
SK-UT-1 NUXZbFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;PbWlEPTB;MD6xOlMhdk1? MYjTRW5ITVJ?
SH-4 M1zZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmVWdKSzVyPUCuNVc{KG6P MVjTRW5ITVJ?
TE-9 M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn5cpRKSzVyPUCuNVgzKG6P MWLTRW5ITVJ?
A253 NHvvbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnjcZhKSzVyPUCuNlA5KG6P MoXoV2FPT0WU
no-10 M2XCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMkGgcm0> MWfTRW5ITVJ?
MMAC-SF NVS4VnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDZWlEPTB;MD6yNVYhdk1? MlyxV2FPT0WU
A101D MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\u[mlEPTB;MD6yNlUhdk1? NWOybHRJW0GQR1XS
NTERA-S-cl-D1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P4fWlEPTB;MD6yOFMhdk1? MkfJV2FPT0WU
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\lT5FKSzVyPUCuNlUhdk1? M3HHO3NCVkeHUh?=
KNS-42 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD3TWM2OD1yLkK1PEBvVQ>? M{T4PHNCVkeHUh?=
LXF-289 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPYTWM2OD1yLkK2PUBvVQ>? NITUR4NUSU6JRWK=
OVCAR-4 M{DkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TnWWlEPTB;MD6yPFkhdk1? MnHnV2FPT0WU
LOUCY MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\IZmlEPTB;MD6yPVMhdk1? M3rJNnNCVkeHUh?=
BB65-RCC MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nBR2lEPTB;MD6zNFQhdk1? MUXTRW5ITVJ?
D-542MG NYG1U4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwM{K5JI5O NHzTWW1USU6JRWK=
ONS-76 NUnxeWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPkTWM2OD1yLkOzJI5O M4D6RXNCVkeHUh?=
BB30-HNC M3zLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2RmlEPTB;MD6zN|Uhdk1? MkLNV2FPT0WU
KS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP2RXZZUUN3ME2wMlM1KG6P MVTTRW5ITVJ?
A388 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zVpNrUUN3ME2wMlM2PiCwTR?= NETlXINUSU6JRWK=
ES8 NIfhdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLlelJxUUN3ME2wMlQhdk1? NIXD[npUSU6JRWK=
MZ2-MEL M{jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD1yLkSwO{BvVQ>? MYPTRW5ITVJ?
HCC2998 NFOxbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXreYM3UUN3ME2wMlQyOiCwTR?= M2nERnNCVkeHUh?=
D-247MG NF34fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli0TWM2OD1yLkSxN{BvVQ>? M2fHbnNCVkeHUh?=
ACN M3nTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNEG3JI5O NI\W[|FUSU6JRWK=
LB2518-MEL Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsV2VKSzVyPUCuOFI2KG6P MmjuV2FPT0WU
ES1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37SdGlEPTB;MD60N{BvVQ>? NWfVVmFkW0GQR1XS
HCE-T NVHiNZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fNTWlEPTB;MD60N|khdk1? NHTiWlZUSU6JRWK=
OS-RC-2 NX\UcGdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDDZ5lKSzVyPUCuOFQhdk1? NXfzNVRyW0GQR1XS
MFH-ino NEnY[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwNESzJI5O M4G1XHNCVkeHUh?=
OCUB-M MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\sTWM2OD1yLkS0O{BvVQ>? NIfWfYVUSU6JRWK=
CP66-MEL M3PsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLV[oRNUUN3ME2wMlQ4OyCwTR?= MV3TRW5ITVJ?
LB771-HNC NHzpRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNEe0JI5O NFTo[|VUSU6JRWK=
DSH1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNEigcm0> Mlj2V2FPT0WU
HUTU-80 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonSTWM2OD1yLkWzN{BvVQ>? M2fsenNCVkeHUh?=
CESS M2LGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r0PWlEPTB;MD61N|ghdk1? MUjTRW5ITVJ?
NCI-H747 NFLBdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwNUO5JI5O MlzHV2FPT0WU
HT-144 M4\tOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H1O2lEPTB;MD61O|Yhdk1? MlXUV2FPT0WU
COLO-829 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHSdXZvUUN3ME2wMlYyPCCwTR?= MWTTRW5ITVJ?
A4-Fuk Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D2eGlEPTB;MD62NlMhdk1? NW[4U4Q3W0GQR1XS
GI-ME-N M{HmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPHXXdUUUN3ME2wMlY{PCCwTR?= NVO0UYZ6W0GQR1XS
LB831-BLC MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PMN2lEPTB;MD62OFEhdk1? Mlq3V2FPT0WU
HOP-62 M3XSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[wWmp4UUN3ME2wMlY1PyCwTR?= M4nhNXNCVkeHUh?=
BB49-HNC M4LicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPBTWM2OD1yLk[1NkBvVQ>? M3vr[3NCVkeHUh?=
D-336MG Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwNkW3JI5O NInqU4dUSU6JRWK=
TK10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P5N2lEPTB;MD62O|khdk1? Mmf6V2FPT0WU
Ramos-2G6-4C10 NUDyVmlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPDTWM2OD1yLk[5N{BvVQ>? NH\qVJpUSU6JRWK=
LB373-MEL-D M3fx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNzDuUS=> MUfTRW5ITVJ?
SF126 NFXvOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYVWRKSzVyPUCuO|AyKG6P NICxZmtUSU6JRWK=
UACC-257 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jw[WlEPTB;MD63NUBvVQ>? NGriXFlUSU6JRWK=
KINGS-1 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH5TWM2OD1yLkeyNkBvVQ>? NITySohUSU6JRWK=
LS-513 M3TIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwN{O5JI5O NV;LfGZWW0GQR1XS
GI-1 M2XKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHVe4pKSzVyPUCuO|Y1KG6P Mlz5V2FPT0WU
ES7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwN{[2JI5O NVT6[|E3W0GQR1XS
LB2241-RCC MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG1RndKSzVyPUCuPFA1KG6P MV3TRW5ITVJ?
D-263MG Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCwVGI5UUN3ME2wMlgxPyCwTR?= Mn[2V2FPT0WU
SW684 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGwRZFzUUN3ME2wMlgzOSCwTR?= MoqzV2FPT0WU
ML-2 NFXOdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHoclU{UUN3ME2wMlgzOSCwTR?= M1;JcnNCVkeHUh?=
SK-LMS-1 NXOyd|NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrnd4NKSzVyPUCuPFU1KG6P MkfZV2FPT0WU
TE-5 NWi2SWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fDOmlEPTB;MD64OlUhdk1? NYDhbpJJW0GQR1XS
QIMR-WIL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13zZ2lEPTB;MD64PFkhdk1? M{XLNHNCVkeHUh?=
NCI-H1355 NWDQc|l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLMNVM6UUN3ME2wMlg6PSCwTR?= NIOwRVVUSU6JRWK=
SNB75 NWnzeoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;WZmlEPTB;MD65NVIhdk1? NXPnb49tW0GQR1XS
RXF393 MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\jW5pKSzVyPUCuPVE1KG6P NVznd2YzW0GQR1XS
IST-MEL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXIVIhKSzVyPUCuPVE4KG6P MXHTRW5ITVJ?
SF268 M3\iWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrtTWM2OD1yLkmyN{BvVQ>? NECwRphUSU6JRWK=
KALS-1 NYP2fWJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\4W3FKSzVyPUCuPVI2KG6P M4Hmc3NCVkeHUh?=
HC-1 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq0TWM2OD1yLkm3OUBvVQ>? NFnJblFUSU6JRWK=
SW872 NUmyNHBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwOUm2JI5O NWK3XYZSW0GQR1XS
PSN1 M4\qWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjYTWM2OD1zLkCxJI5O NGPVWVRUSU6JRWK=
TE-1 NHXZNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nURWlEPTB;MT6wN{BvVQ>? NIDuS2hUSU6JRWK=
TE-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1O2lEPTB;MT6wN{BvVQ>? M13WV3NCVkeHUh?=
RKO MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXmcpRKSzVyPUGuNFYhdk1? MXPTRW5ITVJ?
LC-2-ad NGPmOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;rOHJqUUN3ME2xMlA5KG6P MYHTRW5ITVJ?
SK-MM-2 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvpTWM2OD1zLkC5JI5O NFzh[olUSU6JRWK=
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTvRlRKSzVyPUGuNFkhdk1? M2Lo[XNCVkeHUh?=
MZ7-mel NV;YdJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmwWGxbUUN3ME2xMlA6KG6P M1zYS3NCVkeHUh?=
D-392MG NFnlVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn0VVlMUUN3ME2xMlEhdk1? M{DyZnNCVkeHUh?=
CCRF-CEM NEXhcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMUOgcm0> Mk\yV2FPT0WU
EM-2 NUTQR2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nnfmlEPTB;MT6xOkBvVQ>? M4HD[nNCVkeHUh?=
HAL-01 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXoTWM2OD1zLkG4JI5O NHz6OYRUSU6JRWK=
TE-8 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\GWoxKSzVyPUGuNVkhdk1? MXrTRW5ITVJ?
NCI-H1882 NYftVJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMjDuUS=> NWfrRXN[W0GQR1XS
Daudi M3HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof2TWM2OD1zLkKyJI5O MYDTRW5ITVJ?
BL-41 NY\aeJA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHRbpZKSzVyPUGuNlUhdk1? NVftOno{W0GQR1XS
SR NXTVeYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HiVmlEPTB;MT6yOUBvVQ>? MUXTRW5ITVJ?
KM12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vDS2lEPTB;MT6yO{BvVQ>? MYXTRW5ITVJ?
K5 NWG0Tpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKxTWM2OD1zLkK4JI5O MWrTRW5ITVJ?
A3-KAW MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIToVnJKSzVyPUGuNlghdk1? NYjNU|V3W0GQR1XS
CMK Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHXTWJZUUN3ME2xMlI6KG6P NEjrXndUSU6JRWK=
Calu-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfnZYtKSzVyPUGuNlkhdk1? MonCV2FPT0WU
IST-SL2 NYO4PIE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfBTWM2OD1zLkOxJI5O MVXTRW5ITVJ?
OPM-2 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwM{Ogcm0> M2TkcHNCVkeHUh?=
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkNWlEPTB;MT6zOkBvVQ>? MVXTRW5ITVJ?
ECC12 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zQNWlEPTB;MT6zO{BvVQ>? M2LTc3NCVkeHUh?=
L-540 NEi0PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwM{egcm0> NGLWc|BUSU6JRWK=
CAS-1 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LqfmlEPTB;MT6zO{BvVQ>? M{XzNXNCVkeHUh?=
PF-382 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwNEegcm0> MmLMV2FPT0WU
LS-411N MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULPNol7UUN3ME2xMlU{KG6P MmjzV2FPT0WU
NCI-H69 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;IUmlEPTB;MT61OEBvVQ>? MYHTRW5ITVJ?
NB12 NIrne3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPkXWZCUUN3ME2xMlU3KG6P MWrTRW5ITVJ?
HEL M{fhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPJZXBKSzVyPUGuOlEhdk1? M3W0enNCVkeHUh?=
GCIY M1WzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\NSWZQUUN3ME2xMlYzKG6P MkHhV2FPT0WU
EHEB MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq1XlNoUUN3ME2xMlY4KG6P NHLSO2lUSU6JRWK=
TGBC1TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwN{Ggcm0> NV76NnZqW0GQR1XS
KURAMOCHI M4D2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH34RXpKSzVyPUGuO|Ihdk1? MVjTRW5ITVJ?
U-266 M4S5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[yR2lEPTB;MT63OkBvVQ>? M3;6V3NCVkeHUh?=
LC4-1 M3nEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwN{mgcm0> NX3WfldVW0GQR1XS
NCI-H2126 NFrHdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwODDuUS=> Mn\sV2FPT0WU
NCI-H1092 M{i1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwODDuUS=> NF65OVFUSU6JRWK=
GB-1 NYjUenk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwOEGgcm0> MoLnV2FPT0WU
MV-4-11 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvHTWM2OD1zLkiyJI5O M4Tsb3NCVkeHUh?=
Becker NYHHd4FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vJWGlEPTB;MT64N{BvVQ>? M4nydXNCVkeHUh?=
MPP-89 NGnnU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntPWlEPTB;MT64PUBvVQ>? MXPTRW5ITVJ?
BE-13 M2HhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDvSnpKSzVyPUGuPVMhdk1? M2LIOnNCVkeHUh?=
697 NXTSVVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe0Xo1KSzVyPUGuPVkhdk1? MoPwV2FPT0WU
NKM-1 NWTzTo9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D0NmlEPTB;MjDuUS=> MWTTRW5ITVJ?
NB13 M1\uNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJibl2= MlnRV2FPT0WU
LS-123 M4DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP4TWM2OD1{LkCyJI5O MmWxV2FPT0WU
NB17 NHT6V3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1{LkC0JI5O MUHTRW5ITVJ?
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Px[2lEPTB;Mj6wOUBvVQ>? M1vvPXNCVkeHUh?=
EW-24 NX7vXph7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoftTWM2OD1{LkC4JI5O MoHyV2FPT0WU
NOS-1 NYL3SYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwMUGgcm0> NE\NW|dUSU6JRWK=
BL-70 M1fhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjDbVhKSzVyPUKuNVIhdk1? Mon0V2FPT0WU
GT3TKB M4PaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwMUKgcm0> MnzmV2FPT0WU
HH NH;EZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzWmlEPTB;Mj6xN{BvVQ>? MkfDV2FPT0WU
KE-37 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwMUOgcm0> M4LUW3NCVkeHUh?=
MOLT-4 M1LwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT5eI8{UUN3ME2yMlE{KG6P M{nkZnNCVkeHUh?=
EKVX MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmxTo9xUUN3ME2yMlE1KG6P MUHTRW5ITVJ?
KGN M1PRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jj[2lEPTB;Mj6xOUBvVQ>? NV;He3NzW0GQR1XS
ES4 NGfINmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHFTWM2OD1{LkG2JI5O NI\SWpRUSU6JRWK=
SJSA-1 NXr5[4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzLVmd3UUN3ME2yMlIyKG6P M4HMVXNCVkeHUh?=
KMOE-2 NVjx[GtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX60SGxTUUN3ME2yMlI{KG6P NUPTeoViW0GQR1XS
NB5 M{TabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;vW2x3UUN3ME2yMlI4KG6P NU\ncoxyW0GQR1XS
BC-1 M123OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnFSlRKSzVyPUKuN|Ehdk1? NUXRVm0{W0GQR1XS
NB10 Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37YXmlEPTB;Mj6zNkBvVQ>? M4XzWHNCVkeHUh?=
RPMI-8226 M3O2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwM{Wgcm0> NYTBNVlsW0GQR1XS
SCC-3 NHf1dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXBOXBKSzVyPUKuN|chdk1? M{nlO3NCVkeHUh?=
ARH-77 M13wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HK[mlEPTB;Mj6zPEBvVQ>? NXr3fmN1W0GQR1XS
NCI-H748 M4fNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPbmlEPTB;Mj6zPUBvVQ>? NF7Le5RUSU6JRWK=
KU812 NWn6PHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwNEKgcm0> MX3TRW5ITVJ?
NCI-H64 NEHlVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PeZdlUUN3ME2yMlQ1KG6P MlnSV2FPT0WU
NB69 M4TGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwNE[gcm0> MmXKV2FPT0WU
KNS-81-FD MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwNEigcm0> MX7TRW5ITVJ?
LB1047-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjzTWM2OD1{LkW3JI5O NW\vfoJkW0GQR1XS
EB-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNk[gcm0> NFjzTmdUSU6JRWK=
Mo-T NXzjcJFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDeWlEPTB;Mj63OEBvVQ>? NWPxTW5WW0GQR1XS
EW-16 NUTzdY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwN{Wgcm0> NHrOSmFUSU6JRWK=
CTV-1 M1zUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK0TWM2OD1{Lkigcm0> MnrmV2FPT0WU
ETK-1 NHj5T4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ETmlEPTB;Mj64OEBvVQ>? NGrh[FBUSU6JRWK=
C2BBe1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwOEmgcm0> MXjTRW5ITVJ?
MOLT-16 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYSmNLUUN3ME2yMlg6KG6P NVTkWGpXW0GQR1XS
SW954 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwOTDuUS=> NFT1T|JUSU6JRWK=
HT NVP3PWhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwMEKgcm0> NH70bpNUSU6JRWK=
KARPAS-299 NWT2VXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNwME[gcm0> NYC1eWxkW0GQR1XS
MONO-MAC-6 NFu0[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu1fHVKSzVyPUOuNUBvVQ>? NUCyfHl2W0GQR1XS
CGTH-W-1 NInPbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwMTDuUS=> NEDNVXVUSU6JRWK=
SK-PN-DW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMUSgcm0> NWWz[m9qW0GQR1XS
CW-2 NUW4U3VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXQTWM2OD1|LkKxJI5O NUHuPFFDW0GQR1XS
SK-N-DZ MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNwMk[gcm0> MX7TRW5ITVJ?
NEC8 NI\zVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DzNmlEPTB;Mz6zOUBvVQ>? MlnQV2FPT0WU
LB996-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnXXJVKSzVyPUOuOEBvVQ>? M3\GVnNCVkeHUh?=
DB NXzOWlhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nuXmlEPTB;Mz60NUBvVQ>? M3nF[3NCVkeHUh?=
TE-15 NH;nWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjkTWM2OD1|LkSzJI5O MlrHV2FPT0WU
COR-L88 NVLJcpljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrZWXVKSzVyPUOuOFchdk1? MV\TRW5ITVJ?
LAMA-84 M4SxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjRTWM2OD1|LkS5JI5O NE\aUXlUSU6JRWK=
MEG-01 NGnSU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5[mlEPTB;Mz60PUBvVQ>? MVjTRW5ITVJ?
LOXIMVI NIjKNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX2XlFKSzVyPUOuOUBvVQ>? M13iNnNCVkeHUh?=
RPMI-8402 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHQTWM2OD1|LkWgcm0> NYrMdFJzW0GQR1XS
KARPAS-45 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXrZ2RCUUN3ME2zMlU1KG6P M3q3WXNCVkeHUh?=
HCC1187 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj1TGwzUUN3ME2zMlU1KG6P MVjTRW5ITVJ?
MZ1-PC M3nIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNwNUSgcm0> M2TIPXNCVkeHUh?=
no-11 NUXJNZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTNwNUWgcm0> NFXiWFVUSU6JRWK=
EVSA-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknDTWM2OD1|Lk[gcm0> NWDURVNIW0GQR1XS
DJM-1 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDOVnpKSzVyPUOuOlMhdk1? M3TVdHNCVkeHUh?=
COLO-684 NXjrcXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwNk[gcm0> NIO5WVZUSU6JRWK=
NMC-G1 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j5SmlEPTB;Mz62PEBvVQ>? MljyV2FPT0WU
LC-1F NXfDVZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPHXZFKSzVyPUOuO|Qhdk1? M1voS3NCVkeHUh?=
RL95-2 NFvPTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwN{mgcm0> MkL2V2FPT0WU
COLO-320-HSR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7neIRsUUN3ME2zMlkzKG6P MmPPV2FPT0WU
RCC10RGB NXLvUIwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhendJUUN3ME2zMlk{KG6P M1jJcXNCVkeHUh?=
HD-MY-Z NEfRUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGxc|RRUUN3ME2zMlk{KG6P MX7TRW5ITVJ?
NCI-H2141 NF7HPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDXnpkUUN3ME20MlA2KG6P MnHQV2FPT0WU
K-562 NVvBNlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnVTWM2OD12LkGyJI5O MoTQV2FPT0WU
NCI-H1648 M{OyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLITWM2OD12LkGzJI5O NIPwbopUSU6JRWK=
OMC-1 NWK3UlQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jNVmlEPTB;ND6xPEBvVQ>? MnXmV2FPT0WU
LB647-SCLC M4jWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WzSWlEPTB;ND6yNkBvVQ>? MWnTRW5ITVJ?
TE-12 NFLGWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nCU2lEPTB;ND6yOUBvVQ>? M4r3NXNCVkeHUh?=
NOMO-1 M1rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LBNmlEPTB;ND6zN{BvVQ>? MVHTRW5ITVJ?
Raji MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwNE[gcm0> Mly3V2FPT0WU
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz3W5ltUUN3ME20MlQ6KG6P NFnMXFRUSU6JRWK=
HL-60 NFPz[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzNTWM2OD12Lk[3JI5O MYDTRW5ITVJ?
IST-SL1 M122NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD12Lk[4JI5O Mn3kV2FPT0WU
MHH-PREB-1 NX7zN|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwOE[gcm0> NVjjT|RGW0GQR1XS
MHH-NB-11 M2[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn1bnBKSzVyPUSuPVEhdk1? MkfqV2FPT0WU
JiyoyeP-2003 NIPkcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTVibl2= NXv3[npoW0GQR1XS
SBC-1 NH65V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHWd29zUUN3ME21MlAyKG6P MojMV2FPT0WU
CHP-126 M2XYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwME[gcm0> NH71b|lUSU6JRWK=
LU-139 NF;sb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPxfmtRUUN3ME21MlE{KG6P MULTRW5ITVJ?
NCI-SNU-5 NWruOnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfGc5hKSzVyPUWuNVchdk1? MUXTRW5ITVJ?
SW962 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor2TWM2OD13LkKxJI5O M3TOdXNCVkeHUh?=
EW-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTVwM{Ggcm0> NYrEUYJQW0GQR1XS
NCI-H1417 M1zETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LReGlEPTB;NT61NUBvVQ>? NXPVPZlwW0GQR1XS
LU-65 M4n4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LCO2lEPTB;NT64OEBvVQ>? M{XQdHNCVkeHUh?=
D-502MG NGrmfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXYTWM2OD14LkO3JI5O M3fQN3NCVkeHUh?=
BC-3 NV7qXFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHXTHFtUUN3ME22MlYyKG6P MmnZV2FPT0WU
GDM-1 NFHve3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jYN2lEPTB;Nj63O{BvVQ>? NH23XpVUSU6JRWK=
NCI-H2196 NWnV[Yk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnTZZhvUUN3ME22Mlghdk1? MXPTRW5ITVJ?
NB1 NV7afGpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELrdW1KSzVyPU[uPFghdk1? M3OyPHNCVkeHUh?=
NCI-H345 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OxNGlEPTB;Nz6yJI5O M3XIcHNCVkeHUh?=
SU-DHL-1 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XVPGlEPTB;Nz6yOEBvVQ>? MXPTRW5ITVJ?
JVM-2 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTdwMkigcm0> NYGzXnhrW0GQR1XS
LU-134-A M3TkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTdwM{mgcm0> NHS4TnlUSU6JRWK=
NCI-H1694 M3zEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTdwNUigcm0> NH3ueGtUSU6JRWK=
NCI-SNU-16 NFv3VHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnjTWM2OD15Lk[1JI5O Ml[4V2FPT0WU
L-363 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfVbG9KSzVyPUeuO{BvVQ>? NXfKUFVHW0GQR1XS
KG-1 M{izUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD15Lkm0JI5O M1fNZ3NCVkeHUh?=
MN-60 M3\PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HCVWlEPTB;OD6xOEBvVQ>? M3LPbXNCVkeHUh?=
NB6 NVHnTW5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4U2tKSzVyPUiuOFghdk1? MVTTRW5ITVJ?
MLMA M3yxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O1ZmlEPTB;OD64OUBvVQ>? MWXTRW5ITVJ?
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRThwOEmgcm0> NXjMSZptW0GQR1XS
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTSbHNPUUN3ME25MlAyKG6P MorQV2FPT0WU
DMS-114 M2joR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y4[WlEPTB;OT62NkBvVQ>? M3G5T3NCVkeHUh?=
CTB-1 NUDrS4p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES0NJlKSzVyPUmuOlchdk1? M{TtPHNCVkeHUh?=
NCI-H2081 NIryPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaTWM2OD1zMD6wPUBvVQ>? NXeyWZRFW0GQR1XS
ES5 NGjYSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrjbo5nUUN3ME2xNE4{QCCwTR?= NGjqeFVUSU6JRWK=
HCC1599 M1\CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFzLkmxJI5O NHnxbWtUSU6JRWK=
NCI-H23 NV65dllXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF{LkGyJI5O NV7YWY5YW0GQR1XS
NCI-H1581 M37n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3qSpNIUUN3ME2xNk4zQCCwTR?= MUDTRW5ITVJ?
JVM-3 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfz[|Q4UUN3ME2xNk46QSCwTR?= M{fX[nNCVkeHUh?=
NCI-SNU-1 NX;XXZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCXWlEPTB;MUOuNVkhdk1? MVzTRW5ITVJ?
NB7 M4TvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW4blNKSzVyPUG1MlkzKG6P MUHTRW5ITVJ?
JAR Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF4LkGzJI5O NUGyXZVGW0GQR1XS
TGW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF4LkS4JI5O MkC3V2FPT0WU
U-87-MG NEfnS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjDWHNKSzVyPUG2Mlc3KG6P M2W2fnNCVkeHUh?=
NCI-H1436 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDlTWM2OD1zNz6wNUBvVQ>? M{fXfnNCVkeHUh?=
GOTO NVnsdZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfP[2RKSzVyPUG3MlA3KG6P MmTOV2FPT0WU
COLO-800 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;S[GFKSzVyPUG3MlY1KG6P M2naOnNCVkeHUh?=
MFM-223 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHJWG5KSzVyPUG3MlkyKG6P M1zpUXNCVkeHUh?=
EW-18 M4XTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzyO4tIUUN3ME2xO{46PiCwTR?= MlLlV2FPT0WU
NB14 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1TmlEPTB;MUeuPVghdk1? MVjTRW5ITVJ?
EB2 NYm1UYszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJO2lEPTB;MUiuNFghdk1? MVPTRW5ITVJ?
EoL-1- M3LEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP2TWM2OD1zOD6zNUBvVQ>? NHLwSHNUSU6JRWK=
NCCIT MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[xbHFKSzVyPUG4MlM3KG6P NWfncYc1W0GQR1XS
DG-75 NFj5VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF6Lk[xJI5O NHfwO2NUSU6JRWK=
HCC2218 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn4TG9KSzVyPUG5MlUhdk1? MnPxV2FPT0WU
TE-6 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJyLkC4JI5O MlLDV2FPT0WU
SF539 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[1c2lEPTB;MkCuOlchdk1? M1rTNXNCVkeHUh?=
NCI-H446 M2nST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOzRmpKSzVyPUKxMlE5KG6P M1XCe3NCVkeHUh?=
IST-MES1 NILvS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HROmlEPTB;MkKuO|chdk1? MmmyV2FPT0WU
NCI-H82 NX;2Vo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rHcWlEPTB;MkOuNFIhdk1? M2qxR3NCVkeHUh?=
HCC2157 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ|LkGzJI5O NH;3OGdUSU6JRWK=
EW-12 Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXtZ4NKSzVyPUKzMlE4KG6P M33vWHNCVkeHUh?=
SIMA MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3aTWM2OD1{Mz6zPEBvVQ>? MYrTRW5ITVJ?
DOHH-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXX[WJQUUN3ME2yN{41PSCwTR?= MXzTRW5ITVJ?
IM-9 NV;UbZJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[wfGlEPTB;MkOuOVQhdk1? MXvTRW5ITVJ?
EC-GI-10 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPzbW1VUUN3ME2yOE4zOyCwTR?= M332[3NCVkeHUh?=
HDLM-2 NEnyOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG2dGJTUUN3ME2yOE42PCCwTR?= NY[5[I1yW0GQR1XS
LS-1034 M1vVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7BXYZKSzVyPUK1Mlc2KG6P M{fib3NCVkeHUh?=
REH NV3pRmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\KZ5dKSzVyPUK2MlQyKG6P MW\TRW5ITVJ?
LU-165 NXTMSHN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHTTWM2OD1{Nj63NkBvVQ>? MYjTRW5ITVJ?
NH-12 M4DoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[3VmlEPTB;MkeuOlchdk1? NHOzW|dUSU6JRWK=
WSU-NHL M{fBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPKVmlXUUN3ME2yPE4{QSCwTR?= M4q5SnNCVkeHUh?=
ECC4 NGTsOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn5c3ZKSzVyPUK4Mlc6KG6P NX[1TZpVW0GQR1XS
OCI-AML2 NWjnT3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3LSZZVUUN3ME2yPU43QSCwTR?= MU\TRW5ITVJ?
EW-3 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjtbFBKSzVyPUOwMlU6KG6P MUjTRW5ITVJ?
NCI-H526 M2XoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XES2lEPTB;M{KuOVQhdk1? NUTpdIRSW0GQR1XS
NCI-H719 NGPTV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7hbFJ4UUN3ME2zOE4{OSCwTR?= M3q1O3NCVkeHUh?=
KARPAS-422 NWjYdIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTSTWM2OD1|NT6wOEBvVQ>? M2DxfXNCVkeHUh?=
SK-MEL-1 NHn5W|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1TWM2OD1|NT6xO{BvVQ>? NILqd4JUSU6JRWK=
ES3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\L[G5KSzVyPUO1MlE6KG6P NEXtOGFUSU6JRWK=
UACC-812 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN3LkS0JI5O MVTTRW5ITVJ?
C8166 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID0S29KSzVyPUO1Mlchdk1? M2fjd3NCVkeHUh?=
MDA-MB-134-VI NFriR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLJTWM2OD1|NT64O{BvVQ>? NY\iPFR{W0GQR1XS
D-283MED MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN5Lke5JI5O NFnGd4dUSU6JRWK=
SHP-77 M1\aZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTN6LkCzJI5O NWq0Xmt5W0GQR1XS
NCI-H2227 NWnRWmpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLId5RHUUN3ME20NE41QSCwTR?= MVfTRW5ITVJ?
SKM-1 NVL1dVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR{Lk[zJI5O NGHofHhUSU6JRWK=
L-428 M3PRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LqUmlEPTB;NEOuPFYhdk1? MVHTRW5ITVJ?
RPMI-6666 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR3Lki5JI5O NYjxfZNsW0GQR1XS
NCI-H716 NVm4NplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjqXmZKSzVyPUS4MlgyKG6P MUXTRW5ITVJ?
DMS-79 NVzkNIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVyLkexJI5O M37je3NCVkeHUh?=
RS4-11 M{nZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj3bYpKSzVyPUWwMlg5KG6P M3PUTHNCVkeHUh?=
NCI-H720 NF72WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvUUo5KSzVyPUWxMlEyKG6P MkXOV2FPT0WU
MC-CAR NGfESJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonCTWM2OD13MT61NkBvVQ>? NYrkeFdSW0GQR1XS
TALL-1 NWfBfJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHNNnNKSzVyPUWzMlkyKG6P M2\ZT3NCVkeHUh?=
NCI-N87 NVrYfVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rzSmlEPTB;NUSuNVghdk1? Mmn0V2FPT0WU
P30-OHK NYq3WZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLnN49IUUN3ME21OE43OSCwTR?= MYDTRW5ITVJ?
LP-1 M2LWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XEeWlEPTB;NkGuNlghdk1? M4DoOHNCVkeHUh?=
YT NHvic4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTZzLkigcm0> MUHTRW5ITVJ?
MRK-nu-1 NGLiVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1TGlEPTB;NkGuPFIhdk1? MUXTRW5ITVJ?
BT-474 NFnqbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTZ3IH7N MnjSV2FPT0WU
NCI-H322M NUn2RWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTZ4LkGxJI5O NGfnUFlUSU6JRWK=
NCI-H128 NFnQTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm0TWM2OD15ND63O{BvVQ>? NFP3RmVUSU6JRWK=
KMS-12-PE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny0TWM2OD15Nj6yOEBvVQ>? M1;vUnNCVkeHUh?=
KP-N-YS Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLVO4tKSzVyPUe2Mlc1KG6P NHnWWodUSU6JRWK=
ALL-PO NWjBdWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1PHhKSzVyPUe3MlY3KG6P NWnqRlZOW0GQR1XS
EW-13 M2Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LpXmlEPTB;N{euO|Yhdk1? MV7TRW5ITVJ?
EW-11 NFLMTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTd6LkWyJI5O NYnrU3diW0GQR1XS
SK-N-FI NVH0VoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNNHZzUUN3ME24NE4zKG6P NYTrN|A4W0GQR1XS
CAL-148 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfHUZFoUUN3ME24NU45PCCwTR?= MXTTRW5ITVJ?
RL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTTWM2OD16Nj6wPUBvVQ>? MlHTV2FPT0WU
AM-38 NFjFW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsV2JKSzVyPUi4MlA5KG6P MknaV2FPT0WU
RH-1 NUjGXlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITyW3ZKSzVyPUm5Mlg2KG6P NXm1NWVxW0GQR1XS
NCI-H1770 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFyMj60PUBvVQ>? NWXZ[4YxW0GQR1XS
SIG-M5 NWrQfYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFyNT6wOkBvVQ>? MY\TRW5ITVJ?
GR-ST MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFzMz6zOEBvVQ>? MmDSV2FPT0WU
ST486 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe3[4NSUUN3ME2xNVQvODZibl2= NHnBN3hUSU6JRWK=
NCI-H1650 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojpTWM2OD1zMUWuNlkhdk1? NGjyXmZUSU6JRWK=
MHH-CALL-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFzNT63JI5O NIPJNnRUSU6JRWK=
BV-173 NWL3eoxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{Mj63NUBvVQ>? MmO2V2FPT0WU
MC116 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF2OD64OUBvVQ>? NWnN[5R2W0GQR1XS
NCI-H524 NWm4bpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly0TWM2OD1zNUmuNUBvVQ>? M4T3N3NCVkeHUh?=
SCLC-21H M{nWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX0WYhyUUN3ME2xOVkvPDFibl2= MnPMV2FPT0WU
NCI-H1304 M1THW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF4OT6yNUBvVQ>? MX3TRW5ITVJ?
NCI-H510A MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHYZ|lKSzVyPUG4OU4{PyCwTR?= NHLnUWJUSU6JRWK=
NCI-H209 NETC[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF7Nj61NkBvVQ>? MUPTRW5ITVJ?
KM-H2 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfPXlVXUUN3ME2xPVcvODVibl2= MnvtV2FPT0WU
NCI-H1395 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HOTmlEPTB;MkGwMlE{KG6P NXfWZXY4W0GQR1XS
NCI-H1155 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfJfXVvUUN3ME2yN|AvOzJibl2= NHP0dlZUSU6JRWK=
COR-L279 NX6wSoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5e29KSzVyPUK1Nk4yPyCwTR?= M2rDU3NCVkeHUh?=
NCI-H1299 M2PoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjScY1KSzVyPUK2NU44OSCwTR?= MlLOV2FPT0WU
EW-22 M{LCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJSXNYUUN3ME2yOlMvPzVibl2= MXTTRW5ITVJ?
SK-MEL-2 NGDrVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPHTWM2OD1{OEGuPUBvVQ>? NE\XZY9USU6JRWK=
KASUMI-1 NILaXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTRWHRKSzVyPUK4N{4xPSCwTR?= NH7Kd5RUSU6JRWK=
NCI-H187 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsXJRRUUN3ME2yPFcvODhibl2= MnLjV2FPT0WU
NCI-H2171 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTz[XFKSzVyPUK4PE46OiCwTR?= NHjvdldUSU6JRWK=
LNCaP-Clone-FGC NWjzUVByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXETWM2OD1{OUWuNlYhdk1? NVnrXlhYW0GQR1XS
NCI-H1522 NYPFUGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOzVVF6UUN3ME2zNFcvODVibl2= MYPTRW5ITVJ?
SCH MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O1SGlEPTB;M{KyMlIzKG6P NGW3S3ZUSU6JRWK=
THP-1 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm0fW1KSzVyPUOyNk43KG6P M{LKR3NCVkeHUh?=
SNU-C1 NUPzTWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW5bXVKSzVyPUO2Nk4xQSCwTR?= M1v1VHNCVkeHUh?=
CA46 NEXo[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHYc5NKSzVyPUO3N{43OyCwTR?= MlTNV2FPT0WU
NCI-H1963 NImwZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN6Nj6xPUBvVQ>? NUjyTZpmW0GQR1XS
DEL MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvVdllWUUN3ME2zPVEvOjdibl2= NXTRZ3BKW0GQR1XS
TUR Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwWmlEPTB;M{m2MlYyKG6P NUH4UGN6W0GQR1XS
NCI-H226 NFfKR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HsZWlEPTB;NECzMlI{KG6P MmP4V2FPT0WU
COLO-668 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHqeWsyUUN3ME20NFMvPTdibl2= NH36bXdUSU6JRWK=
CPC-N MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDhT49KSzVyPUSwN{44PyCwTR?= MnTjV2FPT0WU
NCI-H889 M2i5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ucGxKSzVyPUS2NU46OiCwTR?= NFz2[|FUSU6JRWK=
J-RT3-T3-5 NUK2RXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMOGhKSzVyPUWzNk42PyCwTR?= NEL4fnpUSU6JRWK=
MSTO-211H NXvXXok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTV5ND6yOkBvVQ>? MYXTRW5ITVJ?
SCC-15 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXFfJVKSzVyPU[2O{41PyCwTR?= M2CzcXNCVkeHUh?=
SUP-T1 M4\EPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnlNGE4UUN3ME22PFYvODRibl2= NELkXpVUSU6JRWK=
DMS-153 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHSZXNNUUN3ME23OFYvQDNibl2= MXrTRW5ITVJ?
MS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzDTWM2OD15NUmuOFIhdk1? NFv1bIpUSU6JRWK=
TC-YIK MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1TZlKSzVyPUe4NU4xOSCwTR?= MmPJV2FPT0WU
RPMI-8866 NXjKfHFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK1RWJwUUN3ME2xNFA3NjJ6IN88US=> NUXMepRvW0GQR1XS
KY821 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyM{[uNFQh|ryP MX3TRW5ITVJ?
P31-FUJ MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFzMUKuO|Uh|ryP M1PBXnNCVkeHUh?=
COLO-824 NGfobIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD1zMk[xMlc5KM7:TR?= NITUeZhUSU6JRWK=
U-698-M MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLZTWM2OD1{Mk[yMlE2KM7:TR?= M1r3O3NCVkeHUh?=
TE-441-T NFrHUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HYcWlEPTB;MkWyNU44KM7:TR?= MVTTRW5ITVJ?
IMR-5 NVHVRYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnMN|ZXUUN3ME2zOFA6NjZ{IN88US=> MmnlV2FPT0WU
NCI-H1838 NGjXc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3iZnVWUUN3ME20NVg3NjN{IN88US=> NX3remtNW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID